Abbreviated name: D3 L-DOPA
Synonyms: DP-102
Compound class:
Synthetic organic
Comment: Chronic treatment with a substantially lower dose of deuterium-substituted L-DOPA (D3-L-DOPA), compared with L-DOPA (levodopa) produced equal anti-parkinsonian effects and reduced dyskinesia in 6-OHDA-lesioned rats [2]. This new rat study reports similar effect produced by D3-L-DOPA and selegiline plus L-DOPA, respectively, implying adjuvant MAO-B inhibitor treatment may not be necessary with D3-L-DOPA [1]. This compound was proposed for development by the Michael J Fox foundation but there is no ClinicalTrials.gov entry.
|
|
Classification | |
Compound class | Synthetic organic |
IUPAC Name |
(2S)-2-amino-2,3,3-trideuterio-3-(3,4-dihydroxyphenyl)propanoic acid |
Synonyms |
DP-102 |
Database Links | |
GtoPdb PubChem SID | 252166812 |
PubChem CID | 76955701 |
Search Google for chemical match using the InChIKey | WTDRDQBEARUVNC-QZRTVAIESA-N |
Search Google for chemicals with the same backbone | WTDRDQBEARUVNC |
UniChem Compound Search for chemical match using the InChIKey | WTDRDQBEARUVNC-QZRTVAIESA-N |
UniChem Connectivity Search for chemical match using the InChIKey | WTDRDQBEARUVNC-QZRTVAIESA-N |